- Buyers' Guide
- Contact Us
Lohmann managing director Bruno Kaesler said “With the high level of know-how and the focused result-orientation of the scientists here, we are committed to converting these research products into commercial success.
“The range of new vaccines in development and the innovative technology involved represent a great market potential.”
The German company intends to invest at least US$12.82mn in a factory in
Work on the factory should begin in the second half of the year and take a year or two to build and another four years will be needed to get approvals to sell products in